Elevating Excellence - Eirgen Pharma’s Expansion to Advanced Manufacturing

We are delighted to share an exciting milestone in Eirgen Pharma's journey. After 13 months of meticulous planning and construction, we have officially taken possession of Unit 507, our newly expanded state-of-the-art facility located in the IDA Industrial Estate, Waterford. This marks a significant step forward in our ongoing commitment to growth, innovation, and excellence in pharmaceutical manufacturing.

Expanding Our Capabilities to Better Serve You

This expansion introduces an additional 3,500m² of advanced manufacturing capabilities, enhancing our ability to support our global customer base. With this investment, we are strengthening our capacity to meet the evolving needs of our CMO (Contract Manufacturing Organization), CDMO (Contract Development and Manufacturing Organization), and CPO (Contract Packaging Organization) partners.

Our Eirgen qualification team is already onsite, progressing with process installation and the essential facility and process qualification phase. We remain on track for commercialization later this year, ensuring we continue to deliver excellence to our valued partners and patients.

A Legacy of Excellence, A Future of Innovation

Since our establishment in 2005, Eirgen Pharma has been dedicated to developing and supplying High-Potency Oral Solid Dose (OSD) specialty medicines to patients in over 60 countries worldwide. With this expansion, we are not only increasing our presence in Waterford but also reinforcing our global impact in the pharmaceutical industry.

Looking Ahead to 2025 and Beyond

As our new facility comes online in 2025, we look forward to scaling our manufacturing capabilities, upholding our unwavering commitment to quality, and continuing to serve our global partners with industry-leading solutions.

We are excited about what the future holds and invite you to stay connected for more updates as we embark on this new chapter.

Stay up-to-date through LinkedIn - Follow Us!